The PANTHERA trial, a multicenter phase 1b/2 trial, investigated the combination of trastuzumab, pembrolizumab, and chemotherapy in advanced HER2-postiive gastric cancer [47]. This evidence concerns the gene ERBB2 and gastric cancer.